May 16, 2024Open Access

Pharmacogenomics, Race, and Treatment Outcome in Pediatric Acute Myeloid Leukemia

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Disparities in outcomes exist between Black and White patients with acute myeloid leukemia (AML), with Black patients experiencing poorer prognosis compared with their White counterparts.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Lamba et al. (Thu,) studied this question.

synapsesocial.com/papers/68e69af9b6db643587620dc8 https://doi.org/https://doi.org/10.1001/jamanetworkopen.2024.11726

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Pharmacogenetics of Deoxycytidine Kinase: Identification and Characterization of Novel Genetic Variants2007 · 84 citations
2Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML2015 · 22 citations
3World Medical Association Declaration of Helsinki2013 · 29,402 citations
4Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy2015 · 21 citations
5Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia2020 · 82 citations

Me gusta

Guardar

Ver artículo completo